Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate

被引:106
作者
Ved, HS [1 ]
Koenig, ML [1 ]
Dave, JR [1 ]
Doctor, BP [1 ]
机构
[1] WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV NEUROSCI,WASHINGTON,DC 20307
关键词
acetylcholinesterase; calcium mobilization; cholinesterase inhibitors; enriched primary neuronal cell culture; glutamate toxicity; Huperzine A; neuronal survival;
D O I
10.1097/00001756-199703030-00029
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
HUPERZINE A, a potential therapeutic agent for Alzheimer's disease, inhibits acetylcholinesterase in primary cultures derived from forebrain, hippocampus, cortex and cerebellum of embryonic rat brain. Glutamate induces cell death in cultures from all these brain regions. Maximum cell toxicity was observed in cerebellar cultures. Pretreatment of cell cultures with Huperzine A reduced cell toxicity, as evidenced by cytotoxicity assay and general morphology. Huperzine A pretreatment also reduced glutamate-induced calcium mobilization, but did not affect elevations in intraneuronal free Ca2+ ([Ca](i)) caused by KCI or (-)Bay K 8644. The data suggest that Huperzine A could be a potent neuroprotective agent not only where cholinergic neurons are impaired, but also under conditions in which glutamatergic functions are compromised.
引用
收藏
页码:963 / 968
页数:6
相关论文
共 23 条
[1]   ALTERNATIVE EXCITOTOXIC HYPOTHESES [J].
ALBIN, RL ;
GREENAMYRE, JT .
NEUROLOGY, 1992, 42 (04) :733-738
[2]   ALZHEIMER-DISEASE AMYLOID BETA-PROTEIN FORMS CALCIUM CHANNELS IN BILAYER-MEMBRANES - BLOCKADE BY TROMETHAMINE AND ALUMINUM [J].
ARISPE, N ;
ROJAS, E ;
POLLARD, HB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :567-571
[3]  
ASANI Y, 1992, BIOCHEM BIOPH RES CO, V184, P719
[4]  
ASHANI Y, 1994, MOL PHARMACOL, V45, P555
[5]   INOSITOL TRISPHOSPHATE AND CALCIUM SIGNALING [J].
BERRIDGE, MJ .
NATURE, 1993, 361 (6410) :315-325
[6]  
CHOI DW, 1994, ANN NY ACAD SCI, V747, P162
[7]  
CONLEY EC, 1996, ION CHANNEL FACTS BO, P140
[8]  
DAVE JR, 1996, IN PRESS MOL CHEM PA
[9]  
DAVIS RE, 1995, ARZNEIMITTEL-FORSCH, V45-1, P425
[10]  
DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185